Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 3,080 Shares of Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 3,080 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the sale, the director now owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. This represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Denali Therapeutics Trading Up 2.0 %

DNLI stock opened at $21.26 on Friday. The company’s 50-day moving average price is $24.62 and its 200 day moving average price is $24.85. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.33. The company has a market cap of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.35.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period last year, the firm earned ($0.72) earnings per share. On average, equities research analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DNLI has been the subject of several recent research reports. JPMorgan Chase & Co. decreased their target price on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. William Blair started coverage on Denali Therapeutics in a research report on Friday. They set an “outperform” rating for the company. Jefferies Financial Group boosted their target price on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 1st. Stifel Nicolaus upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research report on Monday, December 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.40.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. grew its stake in Denali Therapeutics by 163.7% in the 3rd quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock valued at $1,162,000 after acquiring an additional 24,767 shares during the last quarter. FMR LLC grew its position in shares of Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after purchasing an additional 7,596,508 shares during the last quarter. Candriam S.C.A. grew its position in shares of Denali Therapeutics by 62.2% in the second quarter. Candriam S.C.A. now owns 726,499 shares of the company’s stock valued at $16,869,000 after purchasing an additional 278,621 shares during the last quarter. Algert Global LLC raised its position in shares of Denali Therapeutics by 82.4% during the 3rd quarter. Algert Global LLC now owns 48,630 shares of the company’s stock worth $1,417,000 after purchasing an additional 21,975 shares during the last quarter. Finally, Integral Health Asset Management LLC acquired a new position in shares of Denali Therapeutics during the 2nd quarter worth approximately $7,546,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.